Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Common Equity: 2023-2024

Historic Common Equity for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $198.1 million.

  • Contineum Therapeutics' Common Equity fell 14.16% to $180.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.5 million, marking a year-over-year decrease of 14.16%. This contributed to the annual value of $198.1 million for FY2024, which is 391.55% up from last year.
  • Per Contineum Therapeutics' latest filing, its Common Equity stood at $198.1 million for FY2024, which was up 391.55% from -$67.9 million recorded in FY2023.
  • Contineum Therapeutics' 5-year Common Equity high stood at $198.1 million for FY2024, and its period low was -$67.9 million during FY2023.
  • In the last 2 years, Contineum Therapeutics' Common Equity had a median value of $65.1 million in 2023 and averaged $65.1 million.
  • Data for Contineum Therapeutics' Common Equity shows a peak YoY surged of 391.55% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Common Equity stood at -$67.9 million in 2023, then soared by 391.55% to $198.1 million in 2024.